Corporate profile
Alethia Biotherapeutics is a privately held, Montreal-based biotechnology company engaged in the discovery and development of innovative therapeutics in areas of unmet medical needs.
Alethia currently has three therapeutic monoclonal antibodies in pre-clinical stage. These antibodies are being developed in three therapeutic areas:
-
๏Inhibition of cancer-associated epithelial-to-mesenchymal transition to increase response to chemotherapeutic agents and to prevent tumor metastasis
-
๏Ovarian cancer
-
๏Inhibition of bone degradation that occurs in diseases such as metastatic cancer, acute inflammatory disorders, and severe osteoporosis
Alethia capitalizes on a very strong network of collaborators from the industry, university hospital centers, and federal research institutes that are integral to the long-term success of the organization.
